Embryo development is an orchestrated process that relies on tight regulation of gene expression to guide cell differentiation and fate decisions. Alternative splicing is modulated during development as an additional layer of regulation to reprogram gene expression patterns. TheSrrm2splicing factor has recently been implicated in developmental disorders and diseases, but its role in early mammalian development remains unexplored. Here, we show thatSrrm2dosage is critical for maintaining embryonic stem cell pluripotency and cell identity.Srrm2heterozygosity promotes loss of stemness, characterized by the coexistence of cells expressing naive and formative pluripotency markers, together with extensive changes in gene expression, including genes regulated by serum- response transcription factor and differentiation-related genes. Depletion ofSrrm2by RNA interference in embryonic stem cells shows that the earliest effects of Srrm2 half-dosage are specific alternative splicing events on a small number of genes, followed by expression changes in metabolism and differentiation-related genes. Our findings unveil molecular and cellular roles ofSrrm2in stemness and lineage commitment, shedding light on the roles of splicing regulators in early embryogenesis, developmental diseases and tumorigenesis.Summary statementThis article emphasizes the importance of splicing regulators in early mammalian development by uncovering roles of SRRM2 splicing factor dosage in pluripotency, providing novel insights for a better understanding of Srrm2-related diseases.